biote Corp. (NASDAQ:BTMDW – Get Rating) major shareholder Roystone Capital Management Lp acquired 375,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 7th. The stock was acquired at an average price of $3.25 per share, with a total value of $1,218,750.00. Following the completion of the transaction, the insider now directly owns 2,971,566 shares in the company, valued at approximately $9,657,589.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.

biote Price Performance

Shares of BTMDW opened at $0.34 on Monday. The company has a 50 day simple moving average of $0.36. biote Corp. has a 52-week low of $0.05 and a 52-week high of $1.23.

Hedge Funds Weigh In On biote

Institutional investors and hedge funds have recently modified their holdings of the business. LMR Partners LLP boosted its position in biote by 40.6% during the 3rd quarter. LMR Partners LLP now owns 325,193 shares of the company's stock worth $1,392,000 after acquiring an additional 93,943 shares during the last quarter. BBR Partners LLC bought a new stake in biote in the 3rd quarter valued at $44,000. Cowen AND Company LLC bought a new stake in biote in the 4th quarter valued at $44,000. Jefferies Financial Group Inc. bought a new position in biote during the 4th quarter worth $75,000. Finally, Meteora Capital LLC increased its position in biote by 3,889.3% during the 4th quarter. Meteora Capital LLC now owns 461,278 shares of the company's stock worth $138,000 after buying an additional 449,715 shares during the period.

biote Company Profile

(Get Rating)

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements.

Recommended Stories

• Get a free copy of the StockNews.com research report on biote (BTMDW)
• MarketBeat Week in Review – 2/13 – 2/17
• Deere Stock Raises Outlook and is Ready to Power Higher
• DraftKings Crowning Achievement: Leverage
• Tesla Stock Comeback Is Picking Up Steam
• How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula

Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.